Classification of Medicines
Recent NZ Gazette Notices Relating to Classification
Gazette notice for 8 September 2011. Notice to reclassify pseudoephedrine as a prescription medicine only.
The medicine pseudoephedrine at any concentration and its salts and esters at any concentration are classified as prescription medicines.
Gazette notice for 18 August 2011. Notice to widen public access to oseltamivir and to gazette lovastatin.
Prescription Medicines
Lovastatin; except when present as an unmodified, naturally occurring substance in a food that has not been subject to a manufacturing process other than heating, freezing, drying, preserving, bottling, canning, or packaging in retort pouches
Oseltamivir; except when sold in a pharmacy between the months of April to November inclusive by a registered pharmacist who is satisfied that the medicine is for the treatment of a consumer who is resident in New Zealand, is 12 years of age or more, and currently has the symptoms of influenza
This notice puts in effect the changes recommended by the Medicines Classification Committee at its 45th meeting on Tuesday 12 April 2011.
Prescription Medicines
Afamelanotide
Asenapine
Belimumab
Degarelix
Denosumab
Dronedarone
Eculizumab
Fingolimod
Guaiphenesin; for oral use in medicines containing more than 2% or 200 milligrams per dose form except when specified elsewhere in this schedule; except for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams sold in a pack containing not more than 10 days’ supply approved by the Minister or the Director-General for distribution as a general sale medicine
Icatibant
Indacaterol
Linagliptin
Nitisinone
Nomegestrol
Plerixafor
Prucalopride
Rupatadine
Sapropterin
Tafluprost
Telaprevir
Ticagrelor
Vorinostat
Restricted Medicines
Guaiphenesin; for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams sold in a pack containing more than 10 days’ supply but not more than 30 days’ supply approved by the Minister or the Director-General for distribution as a restricted medicine
Medicines for General Sale
Please note that the following medicines are now available for general sale.
C1 esterase inhibitors
Guaiphenesin; for oral use in medicines containing 2% or less or 200 milligrams or less per dose form; for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams sold in a pack containing not more than 10 days’ supply approved by the Minister or the Director-General for distribution as a general sale medicine